Timing of estradiol treatment after menopause may determine benefit or harm to insulin action

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 12, 2015, Pages 4456-4462

  Pereira, R I ^a   Casey, B A ^a   Swibas, T A ^a   Erickson, C B ^a   Wolfe, P ^b   Van Pelt, R E ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GLUCOSE; INSULIN; PLACEBO;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY MASS; CARDIOMETABOLIC RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG MECHANISM; FAT FREE MASS; FAT MASS; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL THERAPY; HUMAN; HYPERINSULINEMIA; INCIDENCE; INSULIN SENSITIVITY; MENOPAUSAL SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; AGE; DIABETES MELLITUS, TYPE 2; ESTROGEN THERAPY; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; MOTOR ACTIVITY; OBESITY; POSTMENOPAUSE; PROCEDURES; RISK REDUCTION; TREATMENT OUTCOME;

ADIPOSITY; AGE FACTORS; AGED; BODY COMPOSITION; BODY MASS INDEX; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; MOTOR ACTIVITY; POSTMENOPAUSE; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 84950987293     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3084     Document Type: Article

References (39)

1. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause. 2007;14:373-384.
2. Clarkson TB, Melendez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause. 2013;20:342-353.
3. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt). 2006;15:35-44.
4. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8:538-554.
5. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-1477.
6. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95:s1-s66.
7. HarmanSM,BlackDM,Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161:249-260.
8. Hodis HN, Mack WJ, Shoupe D, et al. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis.Menopause. 2015;22:391-401.
9. Bonds DE, Lasser N, Qi L, Brzyski R, et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women?s Health Initiative randomised trial. Diabetologia. 2006;49:459-468.
10. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1-9.
11. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women?s Health Initiative Hormone Trial. Diabetologia. 2004;47:1175-1187.
12. Szmuilowicz ED, Stuenkel CA, Seely EW. Influence of menopause on diabetes and diabetes risk. Nat Rev Endocrinol. 2009;5:553-558.
13. Van Pelt RE, Gozansky WS, Schwartz RS, Kohrt WM. Intravenous estrogens increase insulin clearance and action in postmenopausal women. Am J Physiol Endocrinol Metab. 2003;285:E311-E317.
14. Van Pelt RE, Schwartz RS, Kohrt WM. Insulin secretion and clearance after subacute estradiol administration in postmenopausal women. J Clin Endocrinol Metab. 2008;93:484-490.
15. Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM. Contributions of total and regional fat mass to risk for cardiovascular disease in older women. Am J Physiol Endocrin Metab. 2002; 282:E1023-E1028.
16. Van Pelt RE, Jankowski CM, Gozansky WS, Schwartz RS, Kohrt WM.Lower-body adiposity and metabolic protection in postmenopausal women. J Clin Endocrinol Metab. 2005;90:4573-4578.
17. Kien CL, Ugrasbul F. Prediction of daily energy expenditure during a feeding trial using measurements of resting energy expenditure, fat-free mass, or Harris-Benedict equations. Am J Clin Nutr. 2004; 80:876-880.
18. Dipietro L, Caspersen CJ, Ostfeld AM, Nadel ER. A survey for assessing physical activityamongolder adults.MedSci Sports Exerc. 1993;25:628-642.
19. American Diabetes Association. Screening for diabetes. Diabetes Care. 2002;25:S21-S24.
20. Van Pelt RE, Gozansky WS, Hickner RC, Schwartz RS, Kohrt WM. Acute modulation of adipose tissue lipolysis by intravenous estrogens. Obesity (Silver Spring). 2006;14:2163-2172.
21. Stumvoll M, Jacob S, Wahl HG, et al. Suppression of systemic, intramuscular, and subcutaneous adipose tissue lipolysis by insulin in humans. J Clin Endocrinol Metab. 2000;85:3740-3745.
22. Kohrt WM, Kirwan JP, Staten MA, Bourey RE, King DS, Holloszy JO. Insulin resistance in aging is related to abdominal obesity. Diabetes. 1993;42:273-281.
23. Hodis HN, Mack WJ. Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis. J Steroid Biochem Mol Biol. 2014;142:68-75.
24. Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med. 2009;122:1016-1022.e1.
25. Xing D, Nozell S, Chen YF, Hage F, Oparil S. Estrogen and mechanisms of vascular protection. ArteriosclerThrombVasc Biol. 2009; 29:289-295.
26. Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34:309-338.
27. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008;29:777-822.
28. Natali A, Toschi E, Baldeweg S, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes. 2006;55:1133-1140.
29. Manson JE, Rimm EB, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of noninsulin- dependent diabetes mellitus. Ann Epidemiol. 1992;2:665-673.
30. Gabal LL,Goodman-GruenD, Barrett-Connor E. The effect of postmenopausal estrogen therapy on the risk of non-insulin-dependent diabetes mellitus. Am J Public Health. 1997;87:443-445.
31. Pentti K, Tuppurainen M, Honkanen R, Sandini L, Kroger H, Alhava E, Saarikoski S. Hormone therapy protects from diabetes: the Kuopio Osteoporosis Risk Factor and Prevention Study. Eur J Endocrinol. 2009;160:979-983.
32. Muraki K, Okuya S, Tanizawa Y. Estrogen receptor alpha regulates insulin sensitivity through IRS-1 tyrosine phosphorylation in mature 3T3-L1 adipocytes. Endocr J. 2006;
33. Barros RP, Gabbi C, Morani A, Warner M, Gustafsson JA. Participation of ERalpha and ERbeta in glucose homeostasis in skeletal muscle and white adipose tissue. Am J Physiol Endocrinol Metab. 2009;297:E124-E133.
34. Pedersen SB, Borglum JD, Moller-Pedersen T, Richelsen B. Effects of in vivo estrogen treatment on adipose tissue metabolism and nuclear estrogen receptor binding in isolated rat adipocytes. Mol Cell Endocrinol. 1992;85:13-19.
35. Gonzalez C, Alonso A, Grueso NA, Esteban MM, Fernandez S, Patterson AM. Effect of treatment with different doses of 17-betaestradiol on the insulin receptor. Life Sci. 2002;70:1621-1630.
36. Rogers NH, Witczak CA, Hirshman MF, Goodyear LJ, Greenberg AS. Estradiol stimulates Akt, AMP-activated protein kinase (AMPK) and TBC1D1/4, but not glucose uptake in rat soleus. Biochem Biophys Res Commun. 2009;382:646-650.
37. O?Sullivan AJ, Ho KKY. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab. 1995;80:1783-1788.
38. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138:863-870.
39. WendK,WendP,KrumSA. Tissue-specific effects of loss of estrogen during menopause and aging. Front Endocrinol (Lausanne). 2012; 3:19.